Homology Medicines Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Nov 16

Homology Medicines appoints new CEO, chairperson

Sep 06

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Jul 05

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Jan 28

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Oct 22

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Sep 18

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Aug 14

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

May 22

Homology Medicines (FIXX) Investor Presentation - Slideshow

May 05

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Apr 17

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Mar 13

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Feb 03

CEO

Homology Medicines heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Saswati Chatterjee	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steven S. Gillis	Independent Director	8.2yrs	US$69.06k	0% $ 0
Matthew Patterson	Independent Director	6.2yrs	US$68.56k	0% $ 0
Beverly Davidson	Chairman of Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
Mary Thistle	Independent Director	6yrs	US$76.06k	0% $ 0
Mason Freeman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Morton Cowan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stephen Elledge	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Arthur Tzianabos	Chairman of the Board	7.9yrs	US$1.67m	0.22% $ 120.4k
Jeffrey Poulton	Lead Independent Director	3.7yrs	US$68.56k	0% $ 0
Alise Reicin	Independent Director	4.7yrs	US$68.22k	0% $ 0
Hans-Peter Kiem	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FIXX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Homology Medicines Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings: EPS exceeds analyst expectations

Homology Medicines Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

New major risk - Financial position

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Price target decreased by 57% to US$1.50

Homology Medicines, Inc. Approves Reduction in Workforce

New minor risk - Share price stability

Price target decreased by 17% to US$5.92

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 12% to US$7.14

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Price target decreased to US$8.14

Consensus EPS estimates fall by 92%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Homology Medicines appoints new CEO, chairperson

Consensus forecasts updated

Forecast to breakeven in 2022

Price target decreased to US$8.90

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Consensus forecasts updated

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$12.25

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Price target decreased to US$12.25

Consensus forecasts updated

Price target decreased to US$15.50

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Consensus revenue estimates increase to US$33.2m

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Consensus revenue estimates increase to US$27.7m

Price target decreased to US$24.56

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

Consensus forecasts updated

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Homology Medicines (FIXX) Investor Presentation - Slideshow

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)